<html>
<head>
<META http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>NCT00003900 on 2005_06_30: ClinicalTrials.gov Archive</title>
<link rel="stylesheet" href="/archive/history.css">
<link rel="stylesheet" href="/archive/received.css">
</head>
<body class="received">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="navLinks" class="navLinks"><a href="/archive/NCT00003900">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00003900">&#8593; Current version of this study</a></div><h1>View of NCT00003900 on
  2005_06_30</h1>
<table class="info">
<tr>
<th nowrap>ClinicalTrials Identifier:</th><td>NCT00003900</td>
</tr>
<tr>
<th>Updated:</th><td>2005_06_30</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic<br>Non-small Cell Lung Cancer</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p>Phase II Study of Irinotecan With Docetaxel in Previously Treated Patients<br>With Recurrent Non-Small Cell Lung Cancer</p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PURPOSE: Phase II trial to study the effectiveness of combining irinotecan and docetaxel in treating patients who have recurrent or metastatic non-small cell lung cancer.</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>OBJECTIVES: I. &nbsp;Evaluate the response rate of previously treated patients with recurrent non-small cell lung cancer after treatment with irinotecan and docetaxel.<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;II. &nbsp;Determine the toxicity of this regimen in these patients.<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;III. Determine the overall survival in this patient population.<br>
<br>
<br>
<br>
<br>
<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PROTOCOL OUTLINE: Patients receive irinotecan IV over 90 minutes immediately followed by docetaxel IV over 60 minutes on day 1. Treatment is repeated every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patients are followed every 3 months for 5 years or until death.<br>
<br>
<br>
<br>
<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PROJECTED ACCRUAL:<br>A total of 44 patients will be accrued for this study within 24 months.</p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 2</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Condition</th><td>
         stage IV non-small cell lung cancer
      </td>
</tr>
<tr>
<th>Condition</th><td>
         recurrent non-small cell lung cancer
      </td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: docetaxel</div>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: irinotecan</div>
</td>
</tr>
<tr>
<th>URL</th><td>http://cancer.gov/clinicaltrials/NCCTG-982453</td>
</tr>
<tr>
<th>See also</th><td>
<p>Clinical trial summary from the National Cancer Institute's PDQ&reg; database</p>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>
            No longer recruiting
         </td>
</tr>
<tr>
<th>Start date</th><td>
         1999-10
      </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>PROTOCOL ENTRY CRITERIA:<br>
<br>--Disease Characteristics--<br> &nbsp;- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC); Reconfirmation of NSCLC required only if complete response for greater than 1 year<br>
<br> &nbsp;- Measurable or evaluable disease<br>
<br> &nbsp;- Tumor shrinkage or stability for at least 4 weeks on initial chemotherapy<br>
<br> &nbsp;- CNS metastases allowed, if symptoms controlled for greater than 8 weeks after surgery or radiotherapy<br>
<br>--Prior/Concurrent Therapy--<br>
<br> &nbsp;- Biologic therapy: Not specified<br>
<br> &nbsp;- Chemotherapy: See Disease Characteristics; No greater than 1 prior NSCLC chemotherapy regimen, excluding low dose cisplatin as a radiosensitizer; No prior irinotecan or docetaxel; At least 4 weeks since prior chemotherapy<br>
<br> &nbsp;- Endocrine therapy: Not specified<br>
<br> &nbsp;- Radiotherapy: See Disease Characteristics; At least 4 weeks since prior radiotherapy No prior radiotherapy to greater than 25% of bone marrow<br>
<br> &nbsp;- Surgery: See Disease Characteristics<br>
<br> &nbsp;- Other: No concurrent phenytoin, phenobarbital, or other anticonvulsants<br>
<br>--Patient Characteristics--<br>
<br> &nbsp;- Age: 18 and over<br>
<br> &nbsp;- Performance status: 0-1<br>
<br> &nbsp;- Life expectancy: At least 12 weeks<br>
<br> &nbsp;- Hematopoietic: Absolute neutrophil count at least 1,500/mm3; Platelet count at least 100,000/mm3<br>
<br> &nbsp;- Hepatic: Bilirubin normal; AST no greater than 2 times upper limit of normal (ULN)<br>
<br> &nbsp;- Renal: Creatinine no greater than 2.5 times ULN<br>
<br> &nbsp;- Cardiovascular: No New York Heart Association class III or IV heart disease<br>
<br> &nbsp;- Other: No active infection; At least 5 years since any other prior malignancy except curatively treated basal or squamous cell skin cancer, carcinoma in situ, or other cancers; No grade 2 or worse peripheral neuropathy; No uncontrolled diabetes mellitus; No other serious underlying disease; Not pregnant or nursing; Fertile patients must use effective contraception</p>
</td>
</tr>
<tr>
<th>Minimum age</th><td>18 Years</td>
</tr>
<tr>
<th>Maximum age</th><td>N/A</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>National Cancer Institute (NCI)</td>
</tr>
<tr>
<th>Organization study ID</th><td>CDR0000067071</td>
</tr>
<tr>
<th>Secondary ID</th><td>
            NCCTG-982453
         </td>
</tr>
<tr>
<th>Sponsor</th><td>
               National Cancer Institute (NCI)
            </td>
</tr>
<tr>
<th>Collaborator</th><td>
               North Central Cancer Treatment Group
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               United States: Federal Government
         </td>
</tr>
</table><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div></body>
</html>
